Clean Cells to invest €13 million to create Europe's largest cell bank production site
The expansion is anticipated to speed up development and time-to-market of novel treatments and vaccines for COVID‑19
Clean Cells, a provider of biopharmaceutical product quality control services and manufacturer of starting materials, is to invest €13 million ($15.3 million) for a new production facility in Montaigu‑Vendée (France).
The last 2 years have witnessed a strong upward trend in the production of cell banks for vaccines and therapeutic antibodies — a situation that has pushed Clean Cells, which is part of the Clean Biologics group, to maximum capacity.
By quadrupling its analysis and production capacity for biopharmaceuticals, the group intends to speed up the development and time-to-market of novel treatments and vaccines for COVID‑19.
Increasing the number of its production suites from five to nine, the company will nearly double its production capacity of cell banks for vaccines, therapeutic antibodies and gene therapies.
The new 5,300-m2 laboratories will become the largest site in Europe for biopharmaceuticals quality control services and production of cell banks for innovative drugs.
The construction of the new facility, which started in July 2021, should be completed by September 2022 and will create 80 new jobs, with opportunities available for both engineers and technicians, as well as roles in scientific, logistical, administrative and sales support.
The new site will give Clean Cells access to important additional biopharmaceutical quality control capacity, significantly decreasing time-to-market for these products in Europe. The expansion project, therefore, goes hand-in-hand with France’s strategy of returning industrial activity to French soil.
Clean Cells says it will maintain its capacity for manufacturing virus banks; it will also quadruple its capacity for biosafety tests, allowing the company to respond to the increased demand from existing and new clients.
Related News
-
News Women in Pharma: Moving beyond discussions and into best practice at CPHI Milan
In this second CPHI Milan special of our monthly series, we cover the key takeaways from the Diversity & Wellbeing track held on October 10, 2024. -
News AstraZeneca invests in AI collaboration for cancer drug trials
The British-Swedish pharmaceutical giant is partnering with biotechnology firm Immunai Inc to increase the efficiency of some cancer drug trials. -
News Ozempic and Wegovy prices questioned as Novo Nordisk faces US Senate hearing
The CEO of Novo Nordisk was grilled during a US Senate committee hearing on September 24, 2024, in which the exorbitant prices of the Danish company’s blockbuster drugs Ozempic and Wegovy were called into question. -
News The BIOSECURE Act: implications for the pharma supply chain
On September 9, 2024, the US House of Representatives voted to pass the bill titled the BIOSECURE Act (the Act), which lists several Chinese companies in the pharmaceutical supply chain. The Act will prohibit American companies from contracting or doin... -
News On Track at CPHI Milan: Thermo Fisher Scientific Track Sponsor interview
With CPHI Milan just around the corner, we sat down with some of the sponsors for this year’s conference tracks to discuss the most pressing topics in pharma. -
News CPHI Milan Speaker Spotlight: Pharma Manufacturing and Localisation in Africa
In the run-up to CPHI Milan, we sit down with some of the experts and thought-leaders speaking at this year’s conferences. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Eli Lilly licenses rheumatoid arthritis manufacturing in Africa
American pharmaceutical company Eli Lilly has signed a partnership with Egyptian organisation Eva Pharma to localise manufacturing of rheumatoid arthritis treatments in Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance